ClinicalTrials.gg
CompletedNCT01121575Updated Oct 28, 2015Results posted

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

A Phase 1 interventional study of PF-02341066 and PF-00299804 in Non Small Cell Lung Cancer, sponsored by Pfizer. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-28.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 6 under way, 1 of them phase 3. Crizotinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
13th of 23
70 · median 80
Started
2010
with 2 others
Phase 1
5 of 23
none open now
Registered
4th of 23
by date
Lead sponsor
9 of 23
Pfizer

Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by enrollment, is one of 3 that started in 2010, is one of 5 in phase 1, and was the 4th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About crizotinib

Crizotinib: first FDA approval 2011 (XALKORI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling pathways: the cMET pathway and the EGFR pathway. Both resistance mechanisms can occur at the same time, in the same patient and even in the same tumor. This study combines a second generation EGFR inhibitor and a cMET inhibitor to block both these pathways in order to overcome resistance and treat this disease.

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • Phase 1 acquired resistance to erlotinib or gefitinib cMET inhibitor EGFR inhibitor panHER inhibitor combination trial Crizotinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • advanced non small cell lung cancer (dose escalation phase)
  • acquired resistance to erlotinib or gefitinib (expansion phase)
  • mandatory entrance (expansion phase)

Exclusion criteria

Exclusion Criteria:

  • interstitial lung disease
  • unstable
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Arm 1

    PF-02341066 AND PF-00299804: Patients will be treated with combined cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).

    Drug: PF-02341066 · Drug: PF-00299804

  • Experimental
    Arm 2

    PF-00299804 FOLLOWED BY COMBINED PF-02341066 AND PF-00299804: Patients will be treated with single agent panHER inhibitor (PF-00299804) until disease progression and then with the maximum tolerated combined dose of cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).

    Drug: PF-02341066 · Drug: PF-00299804

Interventions

  • Arm 1: The starting dose will be 200 mg by mouth, twice a day of PF 02341066 in tablet form The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.

    Also known as: cMET inhibitor

  • Arm 1: The starting dose will be 30 mg by mouth once a day of PF-0029804 in tablet form. The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.

    Also known as: panHER inhibitor

  • Arm 2: With progressive disease the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).

    Also known as: cMET inhibitor

  • Arm 2: The dose of 45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).

    Also known as: panHER inhibitor

06

What researchers measure

Primary outcomes

  1. Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase

    AE was any untoward medical occurrence with study drug/ device in a trial participant. Serious adverse event (SAE) was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.

    Time frame: Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)

  2. Overview of Treatment-emergent All Causalities AEs in Expansion Phase

    AE was any untoward medical occurrence with study drug/ device in a trial participant. SAE was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using NCI CTCAE v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.

    Time frame: Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)

  3. Overview of Treatment-emergent, Treatment-related AEs in Escalation Phase

    An AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. SAE was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using NCI CTCAE v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.

    Time frame: Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)

  4. Overview of Treatment-emergent, Treatment-related AEs in Expansion Phase

    An AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. SAE was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using NCI CTCAE v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.

    Time frame: Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)

  5. Number of Participants With Dose Limiting Toxicities (DLTs) in Escalation Phase

    DLTs were those AEs which occurred in Cycle 1 of treatment in Dose Escalation Phase which may be attributed to study drug \[combined Crizotinib (PF-02341066) plus Dacomitinib (PF-00299804)\] without a clear alternative explanation and despite the use of adequate/maximal medical intervention as dictated by local institutional clinical practices or the judgment of the investigator. The following events were considered DLTs (using CTCAE version 4.02);1. Grade ≥4 hematologic events. 2. Grade ≥3 non-hematological events (except Grade 3/4 asymptomatic hypophosphatemia and Grade 3/4 hyperuricemia without signs and symptoms of gout). Nausea, vomiting or diarrhea had to have persisted at Grade 3 or 4 despite maximal medical therapy. Grade 3 hypertension will be considered a DLT only if the event is unmanageable by standard approved pharmacologic agents or if the symptomatic sequelae are identified despite appropriate medical intervention.

    Time frame: Cycle 1 (4 weeks)

Secondary outcomes

  1. Number of Participants With Stable Disease and Stable Disease Duration in Escalation Phase

    If a participant had not achieved an objective response with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) - 1.1 as determined by the investigators, relative to the response evaluable population, but remained stable for at least 6 weeks after first dose, then the best overall response for such a participant was considered as stable disease.

    Time frame: From objective response to date of progression or death due to any cause, whichever occurs first (up to post treatment follow-up as 28-35 days after last dose of study treatment)

  2. Number of Participants With Stable Disease and Stable Disease Duration in Expansion Phase

    If a participant had not achieved an objective response with confirmed complete response (CR) or partial response (PR) according to RECIST (1.1) as determined by the investigators, relative to the response evaluable population, but remained stable for at least 6 weeks after first dose, then the best overall response for such a participant was considered as stable disease.

    Time frame: From objective response to date of progression or death due to any cause, whichever occurs first (up to post treatment follow-up as 28-35 days after last dose of study treatment)

  3. Number of Participants With Objective Response Rate (ORR) in Escalation Phase

    ORR was defined as the percent of participants with CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) determined by study physicians, relative to the response evaluable population. Participants were considered non-responders until proven otherwise. Thus, participants who: 1) Did not have CR or PR while on study, or 2) Did not have a post-baseline tumor evaluation, or 3) Received anti-tumor treatment other than the study medication prior to reaching a CR or PR, or 4) Died, in progress, or drop out for any reason prior to reaching a CR or PR, were counted as non-responders in the assessment of ORR. To be assigned a status of PR or CR, changes in tumor measurements in participants with responding tumors were confirmed by repeated tumor assessment that were performed 4 weeks after the criteria for response were first met.

    Time frame: From objective response to date of progression or death due to any cause, whichever occurs first (up to post treatment follow-up as 28-35 days after last dose of study treatment)

  4. Number of Participants With ORR in Expansion Phase

    ORR was defined as the percent of participants with CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) determined by study physicians, relative to the response evaluable population. Participants were considered non-responders until proven otherwise. Thus, participants who: 1) Did not have CR or PR while on study, or 2) Did not have a post-baseline tumor evaluation, or 3) Received anti-tumor treatment other than the study medication prior to reaching a CR or PR, or 4) Died, in progress, or drop out for any reason prior to reaching a CR or PR, were counted as non-responders in the assessment of ORR. To be assigned a status of PR or CR, changes in tumor measurements in participants with responding tumors were confirmed by repeated tumor assessment that were performed 4 weeks after the criteria for response were first met.

    Time frame: From objective response to date of progression or death due to any cause, whichever occurs first (up to post treatment follow-up as 28-35 days after last dose of study treatment)

  5. Duration of Response for the Only Participant Shown Partial Response in Expansion Phase

    This outcome measure presented the duration of response for one participant in expansion cohort 1 who showed partial response.

    Time frame: From objective response to date of progression or death due to any cause, whichever occurs first (up to post treatment follow-up as 28-35 days after last dose of study treatment)

  6. Progression Free Survival (PFS) in Escalation Phase

    PFS was defined as the time from the date of the first dose to the date of the first documentation of objective tumor progression according to RECIST 1.1 or death on study due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used.

    Time frame: From randomization to objective tumor progression or death (up to post treatment follow-up as 28-35 days after last dose of study treatment)

  7. Progression Free Survival (PFS) in Expansion Phase

    PFS was defined as the time from the date of the first dose to the date of the first documentation of objective tumor progression according to RECIST 1.1 or death on study due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used.

    Time frame: From randomization to objective tumor progression or death (up to post treatment follow-up as 28-35 days after last dose of study treatment)

  8. Expression Analysis of Tumor Biomarkers (HGF, EGFR, and c-Met ) at Baseline Using Immunohistochemistry (IHC) Method

    Tumor biomarkers such as HGF, EGFR, and c-Met were analyzed in tumor cells (neoplastic compartment) of tumor specimens from both expansion cohorts 1 and 2 by IHC. The H score was derived by summing the percentages of cells staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+, where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). Minimum calculated score of 0 to maximum calculated score of 300, where 0 correspond to no expression and maximum score of 300 indicates the strongest expression. However, the biomarker expression level (higher or lower) was not a predictor of outcome.

    Time frame: Baseline

  9. Expression Analysis of Tumor Biomarkers (EGFR, and c-Met) at Baseline Using Fluorescent in Situ Hybridization (FISH) Method

    Expression of tumor biomarkers EGFR and cMet at Baseline (using FISH method) are presented in this outcome measure.

    Time frame: Baseline

  10. Number of Participants With c-Met, HER2, EGFR Amplification and ALK Rearrangement at Baseline Using FISH Method

    Participants showed amplification of c-Met, HER2, and EGFR in the tumor cells and gene rearrangement of ALK are presented in this outcome measure.

    Time frame: Baseline

  11. Plasma Concentration of sMet by Study Visits

    This outcome measure presented the plasma concentration of sMet at different study visits. s-Met was analyzed using an enzyme-linked immunosorbent assay (ELISA).

    Time frame: At screening and Cycle 1 Day 1 (C1D1) (6 hours post dose), and C1D15, C2D1, C2D15 (all predose).

  12. Number of Participants With EGFR Mutation at Baseline

    Sample analyses were performed in accordance to Good Laboratory Practice (GLP) guidance and included mutation detection for EGFR gene.

    Time frame: Baseline

  13. Number of Participants With KRAS Mutation (GLY12CYS) at Baseline

    Sample analyses were performed in accordance to GLP guidance and included mutation detection for KRAS gene.

    Time frame: Baseline

  14. Number of Participants With PIK3CA Mutation at Baseline

    Sample analyses were performed in accordance to GLP guidance and included mutation detection for PIK3CA gene.

    Time frame: Baseline

  15. Number of Participants With ROS1 Gene Translocation at Baseline

    Sample analyses were performed in accordance to GLP guidance and included translocation detection (RNA based) for ROS1 gene.

    Time frame: Baseline

  16. Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Area Under the Plasma Concentration-time Profile From Time Zero to the Last Quantifiable Concentration (AUClast)

    At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included AUClast for crizotinib and PF-06260182. AUClast was calculated using Linear/Log trapezoidal method.

    Time frame: Cycle 1 (C1)/Day 1 (D1), C1D15

  17. Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Area Under the Plasma Concentration-time Curve 10 (AUC10)

    At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). AUC10 was calculated using Linear/Log trapezoidal method. The below analysis table included geometric Mean and Geometric Coefficient of Variation of AUC10 for crizotinib and PF-06260182. Arithmetic mean was presented if the n=2.

    Time frame: C1D1, C1D15

  18. Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Maximum Plasma Concentration (Cmax)

    At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Cmax for crizotinib and PF-06260182. Cmax was observed directly from data.

    Time frame: C1D1, C1D15

  19. Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Time of Last Quantifiable Concentration (Tlast)

    At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tlast for crizotinib and PF-06260182. Tlast was observed directly from data.

    Time frame: C1D1, C1D15

  20. Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase -Time to Maximum Plasma Concentration (Tmax)

    At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tmax for crizotinib and PF-06260182. Tmax was observed directly from data as time of first occurrence.

    Time frame: C1D1, C1D15

  21. Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - AUClast

    At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included AUClast for dacomitinib and PF-05199265. AUClast was calculated using Linear/Log trapezoidal method.

    Time frame: C1D1, C1D15

  22. Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - AUC24

    At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included AUC24 for dacomitinib and PF-05199265. AUC24 was calculated using Linear/Log trapezoidal method.

    Time frame: C1D1, C1D15

  23. Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - Cmax

    At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Cmax for dacomitinib and PF-05199265. Cmax was observed directly from data.

    Time frame: C1D1, C1D15

  24. Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - Tlast

    At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tlast for dacomitinib and PF-05199265. Tlast was observed directly from data.

    Time frame: C1D1, C1D15

  25. Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - Tmax

    At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tmax for dacomitinib and PF-05199265. Tmax was observed directly from data as time of first occurrence.

    Time frame: C1D1, C1D15

  26. Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - AUClast

    Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for AUClast. AUClast was calculated using Linear/Log trapezoidal method.

    Time frame: Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)

  27. Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - AUC10

    Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for AUC10. AUC10 was calculated using Linear/Log trapezoidal method.

    Time frame: Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)

  28. Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Cmin

    Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Cmin. Cmin was observed directly from data.

    Time frame: Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)

  29. Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Cmax

    Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Cmax. Cmax was observed directly from data.

    Time frame: Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)

  30. Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Tlast

    Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Tlast. Tlast was observed directly from data.

    Time frame: Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)

  31. Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Tmax

    Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Tmax. Tmax was observed directly from data as time of first occurrence.

    Time frame: Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)

  32. Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - AUClast

    PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (AUClast) following dacomitinib alone and in combination with crizotinib are summarized in the below table. AUClast was calculated using Linear/Log trapezoidal method.

    Time frame: Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)

  33. Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - AUC24

    PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (AUC24) following dacomitinib alone and in combination with crizotinib are summarized in the below table. AUC24 was calculated using Linear/Log trapezoidal method.

    Time frame: Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)

  34. Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Cmin

    PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Cmin) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Cmin was observed directly from data.

    Time frame: Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)

  35. Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Cmax

    PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Cmax) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Cmax was observed directly from data.

    Time frame: Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)

  36. Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Tlast

    PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Tlast) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Tlast was observed directly from data.

    Time frame: Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)

  37. Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Tmax

    PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Tmax) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Tmax was observed directly from data as time of first occurrence.

    Time frame: Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)

07

Results

Posted Mar 30, 2015

Participant flow

This was a Phase 1, multicenter, open-label, non-randomized study of combined oral crizotinib and oral dacomitinib in participants with advanced non-small cell lung cancer (NSCLC). The study consisted of a dose Escalation Phase and an Expansion Phase. The Expansion Phase consisted of Expansion Cohort 1 and 2 which ran concurrently.

Participant flow — Overall Study
MilestoneCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QDExpansion Cohort 1Expansion Cohort 2
Started146762512
Treated146762512
Completed000000
Not completed146762512
Withdrew: Participant refused further follow-up000051
Withdrew: Unspecified reasons86751310
Withdrew: Death600171

Outcome measures

PrimaryOverview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase

AE was any untoward medical occurrence with study drug/ device in a trial participant. Serious adverse event (SAE) was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.

Time frame:
Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)
Reported as:
Number · participants
Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase
participantsCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Participants with AEs14676
Participants with Grade 3 or 4 AEs9455
Participants with Grade 5 AEs3001
Participants with SAEs6214
PrimaryOverview of Treatment-emergent All Causalities AEs in Expansion Phase

AE was any untoward medical occurrence with study drug/ device in a trial participant. SAE was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using NCI CTCAE v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.

Time frame:
Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)
Reported as:
Number · Participants
Overview of Treatment-emergent All Causalities AEs in Expansion Phase
ParticipantsExpansion Cohort 1Expansion Cohort 2
Participants with AEs2211
Participants with Grade 3 or 4 AEs128
Participants with Grade 5 AEs32
Participants with SAEs88
PrimaryOverview of Treatment-emergent, Treatment-related AEs in Escalation Phase

An AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. SAE was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using NCI CTCAE v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.

Time frame:
Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)
Reported as:
Number · participants
Overview of Treatment-emergent, Treatment-related AEs in Escalation Phase
participantsCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Participants with treatment-related AEs14676
Participants with treatment-related Grade 3/ 4 AEs8333
Participants with treatment-related Grade 5 AEs0000
Participants with treatment-related SAEs1201
PrimaryOverview of Treatment-emergent, Treatment-related AEs in Expansion Phase

An AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. SAE was an AE resulting in death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. AEs were reported from signing of informed consent until 28 days after the last dose of study medication. SAEs were reported after this time frame if considered to be treatment related. The severity of AEs were graded by the investigator using NCI CTCAE v.4.02 and was assessed as Grade 0: no change from normal or reference range; Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling; Grade 5: death related to AE. However the below table included Grade 3, 4, and 5 AEs.

Time frame:
Up to Maximum of treatment duration + 28 days for each participant (could be 295 days)
Reported as:
Number · Participants
Overview of Treatment-emergent, Treatment-related AEs in Expansion Phase
ParticipantsExpansion Cohort 1Expansion Cohort 2
Participants with treatment-related AEs2211
Participants with treatment-related Grade 3/ 4 AEs76
Participants with treatment-related Grade 5 AEs00
Participants with treatment-related SAEs33
PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs) in Escalation Phase

DLTs were those AEs which occurred in Cycle 1 of treatment in Dose Escalation Phase which may be attributed to study drug \[combined Crizotinib (PF-02341066) plus Dacomitinib (PF-00299804)\] without a clear alternative explanation and despite the use of adequate/maximal medical intervention as dictated by local institutional clinical practices or the judgment of the investigator. The following events were considered DLTs (using CTCAE version 4.02);1. Grade ≥4 hematologic events. 2. Grade ≥3 non-hematological events (except Grade 3/4 asymptomatic hypophosphatemia and Grade 3/4 hyperuricemia without signs and symptoms of gout). Nausea, vomiting or diarrhea had to have persisted at Grade 3 or 4 despite maximal medical therapy. Grade 3 hypertension will be considered a DLT only if the event is unmanageable by standard approved pharmacologic agents or if the symptomatic sequelae are identified despite appropriate medical intervention.

Time frame:
Cycle 1 (4 weeks)
Reported as:
Number · Participants
Number of Participants With Dose Limiting Toxicities (DLTs) in Escalation Phase
ParticipantsCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Grade 3 Alanine aminotransferase increased0100
Grade 3 Diarrhoea0100
Grade 3 Mucosal inflammation0010
SecondaryNumber of Participants With Stable Disease and Stable Disease Duration in Escalation Phase

If a participant had not achieved an objective response with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) - 1.1 as determined by the investigators, relative to the response evaluable population, but remained stable for at least 6 weeks after first dose, then the best overall response for such a participant was considered as stable disease.

Time frame:
From objective response to date of progression or death due to any cause, whichever occurs first (up to post treatment follow-up as 28-35 days after last dose of study treatment)
Reported as:
Number · Participants
Number of Participants With Stable Disease and Stable Disease Duration in Escalation Phase
ParticipantsCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Stable Disease10325
0- < 3 months3210
3- < 6 months6113
6- < 9 months1002
SecondaryNumber of Participants With Stable Disease and Stable Disease Duration in Expansion Phase

If a participant had not achieved an objective response with confirmed complete response (CR) or partial response (PR) according to RECIST (1.1) as determined by the investigators, relative to the response evaluable population, but remained stable for at least 6 weeks after first dose, then the best overall response for such a participant was considered as stable disease.

Time frame:
From objective response to date of progression or death due to any cause, whichever occurs first (up to post treatment follow-up as 28-35 days after last dose of study treatment)
Reported as:
Number · Participants
Number of Participants With Stable Disease and Stable Disease Duration in Expansion Phase
ParticipantsExpansion Cohort 1Expansion Cohort 2
Stable Disease65
0- < 3 months10
3- < 6 months44
6- < 9 months11
SecondaryNumber of Participants With Objective Response Rate (ORR) in Escalation Phase

ORR was defined as the percent of participants with CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) determined by study physicians, relative to the response evaluable population. Participants were considered non-responders until proven otherwise. Thus, participants who: 1) Did not have CR or PR while on study, or 2) Did not have a post-baseline tumor evaluation, or 3) Received anti-tumor treatment other than the study medication prior to reaching a CR or PR, or 4) Died, in progress, or drop out for any reason prior to reaching a CR or PR, were counted as non-responders in the assessment of ORR. To be assigned a status of PR or CR, changes in tumor measurements in participants with responding tumors were confirmed by repeated tumor assessment that were performed 4 weeks after the criteria for response were first met.

Time frame:
From objective response to date of progression or death due to any cause, whichever occurs first (up to post treatment follow-up as 28-35 days after last dose of study treatment)
Reported as:
Number · Participants
Number of Participants With Objective Response Rate (ORR) in Escalation Phase
ParticipantsCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Number of Participants With Objective Response Rate (ORR) in Escalation Phase0 (0.0 to 23.2)0 (0.0 to 45.9)0 (0.0 to 41.0)0 (0.0 to 45.9)
SecondaryNumber of Participants With ORR in Expansion Phase

ORR was defined as the percent of participants with CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) determined by study physicians, relative to the response evaluable population. Participants were considered non-responders until proven otherwise. Thus, participants who: 1) Did not have CR or PR while on study, or 2) Did not have a post-baseline tumor evaluation, or 3) Received anti-tumor treatment other than the study medication prior to reaching a CR or PR, or 4) Died, in progress, or drop out for any reason prior to reaching a CR or PR, were counted as non-responders in the assessment of ORR. To be assigned a status of PR or CR, changes in tumor measurements in participants with responding tumors were confirmed by repeated tumor assessment that were performed 4 weeks after the criteria for response were first met.

Time frame:
From objective response to date of progression or death due to any cause, whichever occurs first (up to post treatment follow-up as 28-35 days after last dose of study treatment)
Reported as:
Number · Participants
Number of Participants With ORR in Expansion Phase
ParticipantsExpansion Cohort 1Expansion Cohort 2
Number of Participants With ORR in Expansion Phase1 (0.1 to 22.8)0 (0.0 to 26.5)
SecondaryDuration of Response for the Only Participant Shown Partial Response in Expansion Phase

This outcome measure presented the duration of response for one participant in expansion cohort 1 who showed partial response.

Time frame:
From objective response to date of progression or death due to any cause, whichever occurs first (up to post treatment follow-up as 28-35 days after last dose of study treatment)
Reported as:
Number · Weeks
Duration of Response for the Only Participant Shown Partial Response in Expansion Phase
WeeksExpansion Cohort 1Expansion Cohort 2
Duration of Response for the Only Participant Shown Partial Response in Expansion Phase6.29—
SecondaryProgression Free Survival (PFS) in Escalation Phase

PFS was defined as the time from the date of the first dose to the date of the first documentation of objective tumor progression according to RECIST 1.1 or death on study due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used.

Time frame:
From randomization to objective tumor progression or death (up to post treatment follow-up as 28-35 days after last dose of study treatment)
Reported as:
Median · Months
Progression Free Survival (PFS) in Escalation Phase
MonthsCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Progression Free Survival (PFS) in Escalation Phase3.1 (1.6 to 5.5)3.0 (1.5 to 4.4)1.7 (1.6 to 4.6)4.4 (1.6 to 7.2)
SecondaryProgression Free Survival (PFS) in Expansion Phase

PFS was defined as the time from the date of the first dose to the date of the first documentation of objective tumor progression according to RECIST 1.1 or death on study due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used.

Time frame:
From randomization to objective tumor progression or death (up to post treatment follow-up as 28-35 days after last dose of study treatment)
Reported as:
Median · Months
Progression Free Survival (PFS) in Expansion Phase
MonthsExpansion Cohort 1Expansion Cohort 2
Progression Free Survival (PFS) in Expansion Phase2.1 (1.4 to 4.4)2.1 (1.4 to 5.3)
SecondaryExpression Analysis of Tumor Biomarkers (HGF, EGFR, and c-Met ) at Baseline Using Immunohistochemistry (IHC) Method

Tumor biomarkers such as HGF, EGFR, and c-Met were analyzed in tumor cells (neoplastic compartment) of tumor specimens from both expansion cohorts 1 and 2 by IHC. The H score was derived by summing the percentages of cells staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+, where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). Minimum calculated score of 0 to maximum calculated score of 300, where 0 correspond to no expression and maximum score of 300 indicates the strongest expression. However, the biomarker expression level (higher or lower) was not a predictor of outcome.

Time frame:
Baseline
Reported as:
Median · H-Score
Expression Analysis of Tumor Biomarkers (HGF, EGFR, and c-Met ) at Baseline Using Immunohistochemistry (IHC) Method
H-ScoreExpansion Cohort 1Expansion Cohort 2
HGF (N= 19, 11)40.0 (0 to 280)67.0 (0 to 104)
EGFR (N= 14, 8)193.2 (2 to 300)170.0 (7 to 300)
cMet (N= 19, 11)125.0 (0 to 300)165.0 (20 to 299)
SecondaryExpression Analysis of Tumor Biomarkers (EGFR, and c-Met) at Baseline Using Fluorescent in Situ Hybridization (FISH) Method

Expression of tumor biomarkers EGFR and cMet at Baseline (using FISH method) are presented in this outcome measure.

Time frame:
Baseline
Reported as:
Median · Ratio
Expression Analysis of Tumor Biomarkers (EGFR, and c-Met) at Baseline Using Fluorescent in Situ Hybridization (FISH) Method
RatioExpansion Cohort 1Expansion Cohort 2
Ratio of Red to Green of EGFR (N= 11, 11)1.580 (0.98 to 3.59)1.180 (0.94 to 4.63)
Ratio of Green to Orange for cMET (N = 19, 11)1.040 (0.43 to 2.12)1.000 (0.88 to 1.10)
SecondaryNumber of Participants With c-Met, HER2, EGFR Amplification and ALK Rearrangement at Baseline Using FISH Method

Participants showed amplification of c-Met, HER2, and EGFR in the tumor cells and gene rearrangement of ALK are presented in this outcome measure.

Time frame:
Baseline
Reported as:
Number · Participants
Number of Participants With c-Met, HER2, EGFR Amplification and ALK Rearrangement at Baseline Using FISH Method
ParticipantsExpansion Cohort 1Expansion Cohort 2
c-Met amplification (N= 19, 11)1 (0.98 to 3.59)0 (0.94 to 4.63)
HER2 amplification (N= 19, 7)00
EGFR amplification (N= 11,11)23
ALK rearrangement (N= 19, 11)00
SecondaryPlasma Concentration of sMet by Study Visits

This outcome measure presented the plasma concentration of sMet at different study visits. s-Met was analyzed using an enzyme-linked immunosorbent assay (ELISA).

Time frame:
At screening and Cycle 1 Day 1 (C1D1) (6 hours post dose), and C1D15, C2D1, C2D15 (all predose).
Reported as:
Mean · pg/mL
Plasma Concentration of sMet by Study Visits
pg/mLExpansion Cohort 1Expansion Cohort 2
Baseline at Screening1353411.8 ± 349746.881557000.0 ± 514352.02
C1D11519047.6 ± 230995.771450500.0 ± 553557.13
C1D151483157.9 ± 243904.641676666.7 ± 540246.86
C2D11525666.7 ± 394836.611540000.0 ± 315515.45
C2D151564666.7 ± 224367.901602500.0 ± 126589.89
SecondaryNumber of Participants With EGFR Mutation at Baseline

Sample analyses were performed in accordance to Good Laboratory Practice (GLP) guidance and included mutation detection for EGFR gene.

Time frame:
Baseline
Reported as:
Number · Participants
Number of Participants With EGFR Mutation at Baseline
ParticipantsExpansion Cohort 1Expansion Cohort 2
Exon 18 (G719X)11
Exon 19 (Deletion)63
Exon 20 (T790M)63
Exon 20 (T790M/S768I)10
Exon 20 (S768I)01
Exon 21 (L858R)61
SecondaryNumber of Participants With KRAS Mutation (GLY12CYS) at Baseline

Sample analyses were performed in accordance to GLP guidance and included mutation detection for KRAS gene.

Time frame:
Baseline
Reported as:
Number · Participants
Number of Participants With KRAS Mutation (GLY12CYS) at Baseline
ParticipantsExpansion Cohort 1Expansion Cohort 2
Number of Participants With KRAS Mutation (GLY12CYS) at Baseline10
SecondaryNumber of Participants With PIK3CA Mutation at Baseline

Sample analyses were performed in accordance to GLP guidance and included mutation detection for PIK3CA gene.

Time frame:
Baseline
Reported as:
Number · Participants
Number of Participants With PIK3CA Mutation at Baseline
ParticipantsExpansion Cohort 1Expansion Cohort 2
Exon 20 (M1004I) (N= 14, 6)10
Exon 20 (Q1061K) (N= 14, 6)10
Exon 20 (H1047R) (N= 14, 6)20
Exon 9 (E545K) (N= 14, 6)10
SecondaryNumber of Participants With ROS1 Gene Translocation at Baseline

Sample analyses were performed in accordance to GLP guidance and included translocation detection (RNA based) for ROS1 gene.

Time frame:
Baseline
Reported as:
Number · Participants
Number of Participants With ROS1 Gene Translocation at Baseline
ParticipantsExpansion Cohort 1Expansion Cohort 2
Number of Participants With ROS1 Gene Translocation at Baseline00
SecondaryPlasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Area Under the Plasma Concentration-time Profile From Time Zero to the Last Quantifiable Concentration (AUClast)

At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included AUClast for crizotinib and PF-06260182. AUClast was calculated using Linear/Log trapezoidal method.

Time frame:
Cycle 1 (C1)/Day 1 (D1), C1D15
Reported as:
Geometric mean · ng•hr/mL
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Area Under the Plasma Concentration-time Profile From Time Zero to the Last Quantifiable Concentration (AUClast)
ng•hr/mLCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Crizotinib C1D1 - single dose (n= 11, 6, 7, 6)509.7 ± 62420.8 ± 53506.6 ± 29656.6 ± 65
Crizotinib C1D15 multiple dose (n=8, 3, 6, 5)1759 ± 392464 ± 141732 ± 351672 ± 44
PF-06260182 C1D1 - single dose (n= 11, 6, 7, 6)121.3 ± 76103.2 ± 74121.6 ± 29220.7 ± 55
PF-06260182 C1D15 - multiple dose (n=8, 3, 6, 5)382.3 ± 52593.5 ± 53440.5 ± 37532.0 ± 68
SecondaryPlasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Area Under the Plasma Concentration-time Curve 10 (AUC10)

At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). AUC10 was calculated using Linear/Log trapezoidal method. The below analysis table included geometric Mean and Geometric Coefficient of Variation of AUC10 for crizotinib and PF-06260182. Arithmetic mean was presented if the n=2.

Time frame:
C1D1, C1D15
Reported as:
Geometric mean · ng•hr/mL
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Area Under the Plasma Concentration-time Curve 10 (AUC10)
ng•hr/mLCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Crizotinib C1D1 - single dose (n= 8, 3, 4, 6)624.9 ± 57500.8 ± 9559.6 ± 26655.8 ± 65
Crizotinib C1D15 multiple dose (n= 5, 2, 6, 5)2000 ± 432620 ± NA1732 ± 351644 ± 44
PF-06260182 C1D1 - single dose (n= 8, 3, 4, 6)162.1 ± 57127.6 ± 32141.5 ± 25228.0 ± 57
PF-06260182 C1D15 - multiple dose (n= 5, 2, 6, 5)452.5 ± 48798.0 ± NA473.3 ± 39525.5 ± 68
SecondaryPlasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Maximum Plasma Concentration (Cmax)

At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Cmax for crizotinib and PF-06260182. Cmax was observed directly from data.

Time frame:
C1D1, C1D15
Reported as:
Geometric mean · ng/mL
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Maximum Plasma Concentration (Cmax)
ng/mLCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Crizotinib C1D1 - single dose (n= 11, 6, 7, 6)84.24 ± 5894.13 ± 2290.86 ± 29114.0 ± 61
Crizotinib C1D15 multiple dose (n=8, 3, 6, 5)231.5 ± 41329.7 ± 12218.1 ± 33268.9 ± 77
PF-06260182 C1D1 - single dose (n= 11, 6, 7, 6)18.50 ± 7222.37 ± 2620.97 ± 2934.33 ± 61
PF-06260182 C1D15 - multiple dose (n=8, 3, 6, 5)49.73 ± 5078.45 ± 4457.56 ± 3483.23 ± 91
SecondaryPlasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Time of Last Quantifiable Concentration (Tlast)

At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tlast for crizotinib and PF-06260182. Tlast was observed directly from data.

Time frame:
C1D1, C1D15
Reported as:
Median · Hour
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Time of Last Quantifiable Concentration (Tlast)
HourCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Crizotinib C1D1 - single dose (n= 11, 6, 7, 6)9.92 ± 589.33 ± 229.05 ± 299.75 ± 61
Crizotinib C1D15 multiple dose (n=8, 3, 6, 5)9.29 ± 419.42 ± 259.05 ± 4710.2 ± 35
PF-06260182 C1D1 - single dose (n= 11, 6, 7, 6)9.92 ± 729.33 ± 269.05 ± 299.75 ± 61
PF-06260182 C1D15 - multiple dose (n=8, 3, 6, 5)9.29 ± 509.42 ± 449.05 ± 3410.2 ± 91
SecondaryPlasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase -Time to Maximum Plasma Concentration (Tmax)

At each designated time point, blood samples (3 mL) for pharmacokinetic (PK) analysis of crizotinib and its metabolite, PF 06260182 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tmax for crizotinib and PF-06260182. Tmax was observed directly from data as time of first occurrence.

Time frame:
C1D1, C1D15
Reported as:
Median · Hour
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase -Time to Maximum Plasma Concentration (Tmax)
HourCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Crizotinib C1D1 - single dose (n= 11, 6, 7, 6)3.00 ± 583.53 ± 223.92 ± 293.06 ± 61
Crizotinib C1D15 multiple dose (n=8, 3, 6, 5)1.68 ± 416.17 ± 252.00 ± 476.00 ± 35
PF-06260182 C1D1 - single dose (n= 11, 6, 7, 6)4.07 ± 724.00 ± 263.98 ± 294.99 ± 61
PF-06260182 C1D15 - multiple dose (n=8, 3, 6, 5)4.03 ± 506.17 ± 444.09 ± 346.00 ± 91
SecondaryPlasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - AUClast

At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included AUClast for dacomitinib and PF-05199265. AUClast was calculated using Linear/Log trapezoidal method.

Time frame:
C1D1, C1D15
Reported as:
Geometric mean · ng•hr/mL
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - AUClast
ng•hr/mLCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Dacomitinib C1D1 - single dose (n= 10, 6, 7, 5)208.3 ± 72132.3 ± 153146.3 ± 86307.7 ± 56
Dacomitinib C1D15 multiple dose (n= 8, 4, 6, 4)1339 ± 472343 ± 701212 ± 151775 ± 31
PF-5199265 C1D1 - single dose (n= 8, 6, 6, 6)27.68 ± 807.438 ± 11510.19 ± 19055.00 ± 75
PF-06260182 C1D15 - multiple dose (n= 8, 4, 6, 4)51.48 ± 10852.24 ± 7844.97 ± 90161.0 ± 33
SecondaryPlasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - AUC24

At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included AUC24 for dacomitinib and PF-05199265. AUC24 was calculated using Linear/Log trapezoidal method.

Time frame:
C1D1, C1D15
Reported as:
Geometric mean · ng•hr/mL
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - AUC24
ng•hr/mLCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Dacomitinib C1D1 - single dose (n= 8, 3, 5, 5)252.7 ± 61347.9 ± 26223.4 ± 23306.6 ± 57
Dacomitinib C1D15 multiple dose (n= 8, 4, 6, 4)1336 ± 482334 ± 691203 ± 151745 ± 30
PF-5199265 C1D1 - single dose (n= 9, 3, 5, 6)28.57 ± 8714.80 ± 5116.08 ± 16954.72 ± 76
PF-06260182 C1D15 - multiple dose (n= 8, 4, 6, 4)51.37 ± 10851.97 ± 7844.72 ± 90158.1 ± 31
SecondaryPlasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - Cmax

At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Cmax for dacomitinib and PF-05199265. Cmax was observed directly from data.

Time frame:
C1D1, C1D15
Reported as:
Geometric mean · ng/mL
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - Cmax
ng/mLCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Dacomitinib C1D1 - single dose (n= 10, 6, 7, 5)15.56 ± 5817.49 ± 2312.40 ± 2118.22 ± 64
Dacomitinib C1D15 multiple dose (n= 8, 4, 6, 4)65.00 ± 52122.4 ± 7557.04 ± 1386.81 ± 38
PF-5199265 C1D1 - single dose (n= 10, 6, 6, 7)1.894 ± 890.9888 ± 790.8833 ± 1303.193 ± 74
PF-06260182 C1D15 - multiple dose (n= 8, 4, 6, 4)2.367 ± 1152.649 ± 752.073 ± 957.560 ± 34
SecondaryPlasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - Tlast

At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tlast for dacomitinib and PF-05199265. Tlast was observed directly from data.

Time frame:
C1D1, C1D15
Reported as:
Median · Hour
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - Tlast
HourCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Dacomitinib C1D1 - single dose (n= 11, 6, 7, 5)24.0 ± 8.0015.9 ± 15.923.6 ± 24.024.0 (23.0 to 24.3)
Dacomitinib C1D15 multiple dose (n= 8, 4, 6, 4)24.00 (23.0 to 24.3)23.9 (23.5 to 24.5)23.9 (22.9 to 24.8)24.4 (24.0 to 25.6)
PF-5199265 C1D1 - single dose (n= 8, 6, 6, 6)24.0 (8.00 to 24.6)15.9 (4.08 to 24.0)23.5 (7.55 to 24.1)24.1 (23.0 to 24.5)
PF-06260182 C1D15 - multiple dose (n= 8, 4, 6, 4)24.0 (23.0 to 24.3)23.9 (23.5 to 24.5)23.9 (22.9 to 24.8)24.4 (24.0 to 25.6)
SecondaryPlasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - Tmax

At each designated time point, blood samples (3 mL) for PK analysis of dacomitinib and its metabolite, PF 05199265 were collected in appropriately labeled collection tubes containing dipotassium ethylenediamine tetra-acetic acid (K2EDTA). The below analysis table included Tmax for dacomitinib and PF-05199265. Tmax was observed directly from data as time of first occurrence.

Time frame:
C1D1, C1D15
Reported as:
Median · Hour
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - Tmax
HourCrizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QD
Dacomitinib C1D1 - single dose (n= 11, 6, 7, 5)5.99 ± 8.008.03 ± 15.96.00 ± 24.06.17 (5.92 to 8.00)
Dacomitinib C1D15 multiple dose (n= 8, 4, 6, 4)6.00 (0.0 to 23.1)5.09 (3.97 to 23.5)6.09 (4.15 to 8.13)5.00 (4.00 to 6.00)
PF-5199265 C1D1 - single dose (n= 8, 6, 6, 6)6.95 (3.93 to 24.1)4.04 (3.97 to 8.00)6.78 (3.98 to 8.05)6.08 (3.98 to 24.3)
PF-06260182 C1D15 - multiple dose (n= 8, 4, 6, 4)6.98 (0.0 to 23.1)3.95 (2.00 to 6.17)5.92 (0.0 to 23.9)2.00 (0.0 to 5.98)
SecondaryPlasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - AUClast

Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for AUClast. AUClast was calculated using Linear/Log trapezoidal method.

Time frame:
Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)
Reported as:
Geometric mean · ng•hr/mL
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - AUClast
ng•hr/mLCrizotinib Alone (Expansion Cohort 1)Crizotinib + Dacomitinib (Expansion Cohort 1)
Crizotinib (n = 16, 13)2223 ± 531365 ± 47
PF-06260182 (n = 16, 13)616.3 ± 77356.6 ± 61
Statistical analysis
  • Crizotinib Alone (Expansion Cohort 1) vs Crizotinib + Dacomitinib (Expansion Cohort 1) · Ratio of adjust geometric mean: 69.25 · 90% CI 54.22 to 88.44Ratio of crizotinib + dacomitinib / crizotinib alone adjust geometric mean was analyzed using the mixed effect model and displayed as percentage.
SecondaryPlasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - AUC10

Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for AUC10. AUC10 was calculated using Linear/Log trapezoidal method.

Time frame:
Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)
Reported as:
Geometric mean · ng•hr/mL
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - AUC10
ng•hr/mLCrizotinib Alone (Expansion Cohort 1)Crizotinib + Dacomitinib (Expansion Cohort 1)
Crizotinib (n = 11, 9)2167 ± 561489 ± 44
PF-06260182 (n = 11, 9)634.3 ± 82422.3 ± 55
Statistical analysis
  • Crizotinib Alone (Expansion Cohort 1) vs Crizotinib + Dacomitinib (Expansion Cohort 1) · Ratio of adjust geometric mean: 78.84 · 90% CI 58.90 to 105.54Ratio of crizotinib + dacomitinib / crizotinib alone adjust geometric mean was analyzed using the mixed effect model and displayed as percentage.
SecondaryPlasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Cmin

Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Cmin. Cmin was observed directly from data.

Time frame:
Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)
Reported as:
Geometric mean · ng/mL
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Cmin
ng/mLCrizotinib Alone (Expansion Cohort 1)Crizotinib + Dacomitinib (Expansion Cohort 1)
Crizotinib (n = 16, 13)181.8 ± 64102.8 ± 51
PF-06260182 (n = 16, 13)47.22 ± 9925.53 ± 60
SecondaryPlasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Cmax

Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Cmax. Cmax was observed directly from data.

Time frame:
Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)
Reported as:
Geometric mean · ng/mL
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Cmax
ng/mLCrizotinib Alone (Expansion Cohort 1)Crizotinib + Dacomitinib (Expansion Cohort 1)
Crizotinib (n = 16, 13)306.0 ± 57191.5 ± 43
PF-06260182 (n = 16, 13)82.92 ± 7951.15 ± 56
Statistical analysis
  • Crizotinib Alone (Expansion Cohort 1) vs Crizotinib + Dacomitinib (Expansion Cohort 1) · Ration of adjust geometric mean: 70.60 · 90% CI 54.71 to 91.12Ratio of crizotinib + dacomitinib / crizotinib alone adjust geometric mean was analyzed using the mixed effect model and displayed as percentage.
SecondaryPlasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Tlast

Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Tlast. Tlast was observed directly from data.

Time frame:
Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)
Reported as:
Median · Hour
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Tlast
HourCrizotinib Alone (Expansion Cohort 1)Crizotinib + Dacomitinib (Expansion Cohort 1)
Crizotinib (n = 16, 13)9.650 ± 579.000 ± 43
PF-06260182 (n = 16, 13)9.650 ± 799.000 ± 56
SecondaryPlasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Tmax

Participants were evaluated for the effect of dacomitinib on steady-state PK of crizotinib. PK of crizotinib alone was evaluated on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) after a lead in period of continuous BID dosing of crizotinib for approximately 12 days (±2 days). PK of crizotinib and dacomitinib in combination treatment was evaluated on Day 1 of Cycle 2. Blood samples for crizotinib full PK were to be collected on Day -1 and Day 1 of Cycle 2. The below table included PK data for Tmax. Tmax was observed directly from data as time of first occurrence.

Time frame:
Day -1 (crizotinib alone), C2D1 (crizotinib + dacomitinib)
Reported as:
Median · Hour
Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Tmax
HourCrizotinib Alone (Expansion Cohort 1)Crizotinib + Dacomitinib (Expansion Cohort 1)
Crizotinib (n = 16, 13)2.04 ± 573.20 ± 43
PF-06260182 (n = 16, 13)3.96 ± 793.95 ± 56
SecondaryPlasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - AUClast

PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (AUClast) following dacomitinib alone and in combination with crizotinib are summarized in the below table. AUClast was calculated using Linear/Log trapezoidal method.

Time frame:
Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)
Reported as:
Geometric mean · ng•hr/mL
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - AUClast
ng•hr/mLDacomitinib Alone (Expansion Cohort 2)Crizotinib + Dacomitinib (Expansion Cohort 2)
Dacomitinib (n = 6, 5)1016 ± 451148 ± 44
PF-05199265 (n = 7, 6)80.94 ± 59878.22 ± 42
Statistical analysis
  • Dacomitinib Alone (Expansion Cohort 2) vs Crizotinib + Dacomitinib (Expansion Cohort 2) · Ratio of adjust geometric mean: 117.81 · 90% CI 64.97 to 213.61Ratio of crizotinib + dacomitinib / dacomitinib alone adjust geometric mean was analyzed using the mixed effect model and displayed as percentage.
SecondaryPlasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - AUC24

PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (AUC24) following dacomitinib alone and in combination with crizotinib are summarized in the below table. AUC24 was calculated using Linear/Log trapezoidal method.

Time frame:
Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)
Reported as:
Geometric mean · ng•hr/mL
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - AUC24
ng•hr/mLDacomitinib Alone (Expansion Cohort 2)Crizotinib + Dacomitinib (Expansion Cohort 2)
Dacomitinib (n = 6, 5)995.7 ± 451148 ± 44
PF-05199265 (n = 7, 6)78.57 ± 58778.36 ± 42
Statistical analysis
  • Dacomitinib Alone (Expansion Cohort 2) vs Crizotinib + Dacomitinib (Expansion Cohort 2) · Ratio of adjust geometric mean: 121.90 · 90% CI 70.20 to 211.66Ratio of crizotinib + dacomitinib / dacomitinib alone adjust geometric mean was analyzed using the mixed effect model and displayed as percentage.
SecondaryPlasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Cmin

PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Cmin) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Cmin was observed directly from data.

Time frame:
Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)
Reported as:
Geometric mean · ng/mL
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Cmin
ng/mLDacomitinib Alone (Expansion Cohort 2)Crizotinib + Dacomitinib (Expansion Cohort 2)
Dacomitinib (n = 6, 5)33.11 ± 5839.92 ± 47
PF-05199265 (n = 7, 6)5.440 ± 832.901 ± 47
SecondaryPlasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Cmax

PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Cmax) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Cmax was observed directly from data.

Time frame:
Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)
Reported as:
Geometric mean · ng/mL
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Cmax
ng/mLDacomitinib Alone (Expansion Cohort 2)Crizotinib + Dacomitinib (Expansion Cohort 2)
Dacomitinib (n = 6, 5)47.15 ± 4459.58 ± 49
PF-05199265 (n = 7, 6)4.222 ± 3754.070 ± 37
Statistical analysis
  • Dacomitinib Alone (Expansion Cohort 2) vs Crizotinib + Dacomitinib (Expansion Cohort 2) · Ratio of adjust geometric mean: 130.57 · 90% CI 82.46 to 206.73Ratio of crizotinib + dacomitinib / dacomitinib alone adjust geometric mean was analyzed using the mixed effect model and displayed as percentage.
SecondaryPlasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Tlast

PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Tlast) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Tlast was observed directly from data.

Time frame:
Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)
Reported as:
Median · Hour
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Tlast
HourDacomitinib Alone (Expansion Cohort 2)Crizotinib + Dacomitinib (Expansion Cohort 2)
Dacomitinib (n = 6, 5)24.40 ± 4423.80 ± 49
PF-05199265 (n = 7, 6)24.50 ± 37523.80 ± 37
SecondaryPlasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Tmax

PK samples for full PK evaluation of dacomitinib were drawn on Day -1 (one day before C1D1 on which the combination treatment of crizotinib and dacomitinib started) and on C2D1. Dacomitinib and PF-05199265 PK parameter (Tmax) following dacomitinib alone and in combination with crizotinib are summarized in the below table. Tmax was observed directly from data as time of first occurrence.

Time frame:
Day -1 (dacomitinib alone), C2D1 (crizotinib + dacomitinib)
Reported as:
Median · Hour
Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Tmax
HourDacomitinib Alone (Expansion Cohort 2)Crizotinib + Dacomitinib (Expansion Cohort 2)
Dacomitinib (n = 6, 5)16.0 ± 445.92 ± 49
PF-05199265 (n = 7, 6)5.90 ± 3754.35 ± 37

Adverse events

Collected over Up to Maximum of treatment duration + 28 days for each participant (could be 295 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-02341066, 200 mg BID/ PF-00299804, 30 mg QD—6/14 (42.9%)14/14 (100%)
PF-02341066, 200 mg BID/ PF-00299804, 45 mg QD—2/6 (33.3%)6/6 (100%)
PF-02341066, 250 mg BID/ PF-00299804, 30 mg QD—1/7 (14.3%)7/7 (100%)
PF-02341066, 250 mg QD/ PF-00299804, 45 mg QD—4/6 (66.7%)6/6 (100%)
Expansion Cohort 1—9/25 (36%)25/25 (100%)
Expansion Cohort 2—9/12 (75%)12/12 (100%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPF-02341066, 200 mg BID/ PF-00299804, 30 mg QDPF-02341066, 200 mg BID/ PF-00299804, 45 mg QDPF-02341066, 250 mg BID/ PF-00299804, 30 mg QDPF-02341066, 250 mg QD/ PF-00299804, 45 mg QDExpansion Cohort 1Expansion Cohort 2
AnaemiaBlood and lymphatic system disorders0/140/60/71/60/250/12
Febrile neutropeniaBlood and lymphatic system disorders0/140/60/71/60/250/12
SyncopeCardiac disorders0/140/60/71/60/250/12
DiarrhoeaGastrointestinal disorders0/140/60/70/62/252/12
NauseaGastrointestinal disorders0/140/60/71/60/251/12
Disease progressionGeneral disorders1/140/60/70/62/252/12
HypersensitivityImmune system disorders0/141/60/70/60/250/12
Blood creatinine increasedInvestigations0/140/60/71/60/250/12
DehydrationMetabolism and nutrition disorders0/140/60/71/61/250/12
HyperuricaemiaMetabolism and nutrition disorders1/140/60/71/60/250/12
Most frequent other events
Showing 10 of 181
Most frequent other events
EventPF-02341066, 200 mg BID/ PF-00299804, 30 mg QDPF-02341066, 200 mg BID/ PF-00299804, 45 mg QDPF-02341066, 250 mg BID/ PF-00299804, 30 mg QDPF-02341066, 250 mg QD/ PF-00299804, 45 mg QDExpansion Cohort 1Expansion Cohort 2
DiarrhoeaGastrointestinal disorders12/146/66/76/619/2510/12
NauseaGastrointestinal disorders10/144/65/76/619/2510/12
VomitingGastrointestinal disorders9/142/61/75/611/256/12
Decreased appetiteMetabolism and nutrition disorders7/144/63/73/610/255/12
RashSkin and subcutaneous tissue disorders9/143/63/73/65/257/12
FatigueGeneral disorders7/143/63/73/613/257/12
ParonychiaInfections and infestations6/142/61/73/68/257/12
Oedema peripheralGeneral disorders7/142/63/71/67/254/12
EpistaxisRespiratory, thoracic and mediastinal disorders3/143/60/70/62/250/12
Dermatitis acneiformSkin and subcutaneous tissue disorders4/141/61/73/610/252/12

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Crizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QDExpansion Cohort 1Expansion Cohort 2Total
Mean53.6 ± 9.8761.7 ± 7.5354.7 ± 11.3462.2 ± 13.6161.8 ± 10.8359.6 ± 11.7459.1 ± 11.05
Sex: Female, Male
Sex: Female, Male(Participants)Crizotinib 200 mg BID/ Dacomitinib 30 mg QDCrizotinib 200 mg BID/ Dacomitinib 45 mg QDCrizotinib 250 mg BID/ Dacomitinib 30 mg QDCrizotinib 250 mg QD/ Dacomitinib 45 mg QDExpansion Cohort 1Expansion Cohort 2Total
Female556216943
Male91149327
08

Study locations

10 sites
  • Clinical Trials Office University of Colorado Hospital (CTO)
    Aurora, Colorado 80045, United States
  • DRUG SHIPMENT: University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Rocky Mountain Lions Eye Institute
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • CCR, National Cancer Institute
    Bethesda, Maryland 20892, United States
  • Drug Shipment Only
    Boston, Massachusetts 02114, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Drug Shipment Only
    Boston, Massachusetts 02215, United States
  • Peter MacCallum Cancer Centre, Division of Haematology and Medical Oncology
    East Melbourne, Victoria 3002, Australia
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2010
First posted
May 12, 2010
Start
Aug 2010
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results first posted
Mar 30, 2015
Last update
Oct 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01121575
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 12, 2010
Start date
Aug 2010
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Mar 30, 2015
Last update
Oct 28, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Crizotinib · Dacomitinib

Start the discussion